A phase 1/2 dose escalation and expansion study of bemcentinib (BGB324), a first-in-class, selective AXL inhibitor, with docetaxel in patients with previously treated non-squamous NSCLC.

Sawsan Rashdan,Jessica N. Williams,Penny Currykosky,Farjana Fattah,Jonathan Padro,Katarzyna Wnuk-Lipinska,Gro Gausdal,Anthony Brown,David R. Micklem,Robert J. Holt,James B. Lorens,Murray Yule,David E. Gerber

A phase 1/2 dose escalation and expansion study of bemcentinib (BGB324), a first-in-class, selective AXL inhibitor, with docetaxel in patients with previously treated non-squamous NSCLC.

2018

Sawsan Rashdan
Jessica N. Williams
Penny Currykosky
Farjana Fattah
Jonathan Padro
Katarzyna Wnuk-Lipinska
Gro Gausdal
Anthony Brown
David R. Micklem
Robert J. Holt
James B. Lorens
Murray Yule
David E. Gerber

e21043Background: AXL is a receptor tyrosine kinase expressed on a variety of tumours as well as innate immune cells. AXL functions to regulate multiple cellular processes including tumour cell sur...

Keywords:

Pathology
Cancer research
Docetaxel
Medicine
Innate immune system
previously treated
in patient
dose escalation
Cell
Receptor tyrosine kinase
non squamous

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations